Associations of depression with impaired glucose regulation, newly diagnosed diabetes and previously diagnosed diabetes in Chinese adults

2015 ◽  
Vol 32 (7) ◽  
pp. 935-943 ◽  
Author(s):  
J. C. Sun ◽  
M. Xu ◽  
J. L. Lu ◽  
Y. F. Bi ◽  
Y. M. Mu ◽  
...  
Keyword(s):  
Glucose Regulation ◽  
Impaired Glucose Regulation ◽  
Newly Diagnosed ◽  
Chinese Adults ◽  
Diagnosed Diabetes ◽  
Newly Diagnosed Diabetes

scholarly journals Prevalence and identification of type 1 diabetes in Chinese adults with newly diagnosed diabetes

2019 ◽  
Vol Volume 12 ◽  
pp. 1527-1541
Author(s):  
Xiaohan Tang ◽  
Xiang Yan ◽  
Houde Zhou ◽  
Xilin Yang ◽  
Xiaohong Niu ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Newly Diagnosed ◽  
Chinese Adults ◽  
Diagnosed Diabetes ◽  
Newly Diagnosed Diabetes

scholarly journals Prevalence of Abnormal Glucose Regulation according to Different Diagnostic Criteria in Ischaemic Stroke without a History of Diabetes

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Xinmiao Zhang ◽  
Qiuyan Shi ◽  
Huaguang Zheng ◽  
Qian Jia ◽  
Xingquan Zhao ◽  
...  
Keyword(s):  
Ischaemic Stroke ◽  
Glucose Regulation ◽  
Oral Glucose ◽  
Haemoglobin A1c ◽  
Newly Diagnosed ◽  
Stroke Patients ◽  
Abnormal Glucose Regulation ◽  
History Of ◽  
Diagnosed Diabetes ◽  
Newly Diagnosed Diabetes

We aimed to investigate the prevalence and distribution of abnormal glucose regulation, including prediabetes and newly diagnosed diabetes, according to different criteria in ischaemic stroke patients without a history of diabetes. Data were derived from a representative cohort across China. Prediabetes was defined as fasting plasma glucose (FPG) 5.6–6.9 mmol/L or 2-hour oral glucose tolerance test (OGTT) 7.8–11.0 mmol/L or haemoglobin A1c (HbA1c) 5.7–6.4%. Newly diagnosed diabetes was defined as FPG ≥ 7.0 mmol/L, 2 h OGTT ≥ 11.1 mmol/L or HbA1c ≥ 6.5%. Among 1251 ischaemic stroke patients, 471 (37.5%) were detected as prediabetes and 539 (43.1%) were detected as newly diagnosed diabetes. Prediabetes was present in 118 (9.4%), 290 (23.2%) and 314 (25.1%) stroke patients, and newly diagnosed diabetes was present in 138 (11.0%), 370 (29.6%), and 365 (29.2%) stroke patients, based on FPG, 2 h OGTT, and HbA1c criteria, respectively. Dependency on FPG alone would have missed 74.9% of patients in the prediabetes range and 74.4% of patients in the diabetes range. Our study demonstrated a high prevalence of prediabetes and diabetes in ischaemic stroke patients without a history of diabetes. OGTT and HbA1c helped detect the majority of prediabetes and newly diagnosed diabetes in ischaemic stroke patients.

scholarly journals Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial

2019 ◽  
Vol 8 (4) ◽  
pp. 318-325 ◽  
Author(s):  
Xiao-jun Zhou ◽  
Lin Ding ◽  
Jia-xin Liu ◽  
Le-qun Su ◽  
Jian-jun Dong ◽  
...  
Keyword(s):  
Randomized Study ◽  
Secondary Outcome ◽  
Outcome Analysis ◽  
Newly Diagnosed ◽  
Baseline Hba1c ◽  
Chinese Adults ◽  
Once Daily ◽  
Lowering Effect ◽  
Diagnosed Diabetes ◽  
Newly Diagnosed Diabetes

Aims To investigate the difference in the efficacy among dipeptidyl peptidase-4 (DPP-4) inhibitors in Chinese adults with newly diagnosed diabetes. Materials and methods In a multicenter, randomized study, we enrolled adults who were either treatment naive or off prior anti-hyperglycemic therapy for at least 3 months. Eligible patients had hemoglobin A1c (HbA1c) concentrations of 6.5–9.5%. Three hundred patients had been randomly allocated to sitagliptin 100 mg, once daily; vildagliptin 50 mg, twice daily and saxagliptin 5 mg, once daily for 12 weeks. Patients and investigators were masked to treatment assignment. The primary endpoint was change from baseline in HbA1c at week 12. This study was completed and registered with ClinicalTrials.gov, number NCT 01703637. Results Totally 277 patients were enrolled in the final analysis, and 93 patients received sitagliptin, 94 received vildagliptin and 90 received saxagliptin. Compared with baseline, adjusted mean differences in change from baseline HbA1c at week 12 were −0.50% (95% CI: −0.20 to −0.90), −0.65% (95% CI: −0.40 to −1.40), −0.70 (95% CI: −0.50 to −1.00) for sitagliptin, vildagliptin and saxagliptin group, respectively. The overall HbA1c-lowering effect was similar for all three selected DPP-4 inhibitors after adjustment for age and baseline HbA1c. Notably, in secondary outcome analysis, patients in vildagliptin group showed a significant decrease in total cholesterol levels, compared with participants in sitagliptin and saxagliptin groups. No significant between-group difference was shown in adverse events (AE). Conclusions The overall HbA1c-lowering effect and incidence of AE were similar for sitagliptin, vildagliptin and saxagliptin in Chinese adults with newly diagnosed diabetes.

Abstract #502: Newly Diagnosed Diabetes Mellitus Presenting as Chylomicronemia Syndrome an Uncommon Presentation of a Common Disease

2016 ◽  
Vol 22 ◽  
pp. 116
Author(s):  
Maha Sulieman ◽  
Delamo Isaac Bekele ◽  
Jennifer Marquita Carter ◽  
Rabia Cherqaoui ◽  
Vijaya Ganta ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Common Disease ◽  
Newly Diagnosed ◽  
Uncommon Presentation ◽  
Diagnosed Diabetes ◽  
Newly Diagnosed Diabetes

A Clinical Study of Microvascular Complications in Newly Diagnosed Diabetes Mellitus Patients

2011 ◽  
Vol 4 (2) ◽  
pp. 12-14
Author(s):  
Dr Yash Patel ◽  
◽  
Dr Ashay Shingare ◽  
Dr Gautam Kalita ◽  
Dr Vinaya Bhandari
Keyword(s):  
Diabetes Mellitus ◽  
Clinical Study ◽  
Microvascular Complications ◽  
Newly Diagnosed ◽  
Diagnosed Diabetes ◽  
Newly Diagnosed Diabetes
Sign in / Sign up

Export Citation Format

Share Document